[
    {
        "id": 2798,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "NCT02948959",
        "has_trial_insight_page": 0,
        "indication": "Asthma - 6-11 year-olds",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-20",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-expands-approval-of-dupixent-dupilumab-to-include-children-aged-6-to-11-years-with-moderate-to-severe-asthma-301405141.html",
        "note": "Approved October 20, 2021. ",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2798,
        "drug_name": "DUPIXENT (dupilumab)",
        "clinical_trial_id": "NCT02948959",
        "has_trial_insight_page": 0,
        "indication": "Asthma - 6-11 year-olds",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-20",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-expands-approval-of-dupixent-dupilumab-to-include-children-aged-6-to-11-years-with-moderate-to-severe-asthma-301405141.html",
        "note": "Approved October 20, 2021. ",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7404,
        "drug_name": "JNJ-78436735 (Ad26.COV2-S) -  (ENSEMBLE-2)",
        "clinical_trial_id": "NCT04614948",
        "has_trial_insight_page": 1,
        "indication": "COVID-19 vaccine - two-dose regimen",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-20",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/johnson--johnson-covid-19-vaccine-booster-shot-authorized-for-emergency-use-by-us-fda-301405196.html",
        "note": "EUA for second dose for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine, noted October 20, 2021.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5942,
        "drug_name": "Susvimo (ranibizumab injection)",
        "clinical_trial_id": "NCT03677934",
        "has_trial_insight_page": 0,
        "indication": "Neovascular Age-Related Macular Degeneration",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-22",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/10\/22\/2319366\/0\/en\/FDA-approves-Roche-s-Susvimo-a-first-of-its-kind-therapeutic-approach-for-neovascular-or-wet-age-related-macular-degeneration-nAMD.html",
        "note": "Approved October 22, 2021.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2596,
        "drug_name": "Balstilimab",
        "clinical_trial_id": "NCT03104699",
        "has_trial_insight_page": 0,
        "indication": "Cervical cancer",
        "label": "BLA Filing",
        "value": "blaFiling",
        "simplified_stage": "phase4",
        "stageid": 12,
        "stage_name": "BLA Filing",
        "date": "2021-10-22",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/10\/22\/2319117\/8060\/en\/Agenus-Provides-Update-on-Balstilimab-Development.html",
        "note": "BLA voluntarily withdrawn October 22, 2021. ",
        "company_entity_id": 324,
        "company_ticker": "AGEN",
        "company_name": "Agenus Inc.",
        "company_price": "0.6692",
        "company_change": 0,
        "company_percent_change": -0.62,
        "company_optionable": 1,
        "company_number_of_shares": 381495471,
        "price_change_sparkline": [
            [
                0.6672,
                1706677200
            ],
            [
                0.6352,
                1706763600
            ],
            [
                0.6372,
                1706850000
            ],
            [
                0.6323,
                1707109200
            ],
            [
                0.7043,
                1707195600
            ],
            [
                0.6799,
                1707282000
            ],
            [
                0.6973,
                1707368400
            ],
            [
                0.7481,
                1707454800
            ],
            [
                0.8093,
                1707714000
            ],
            [
                0.7601,
                1707800400
            ],
            [
                0.9279,
                1707886800
            ],
            [
                0.6538,
                1707973200
            ],
            [
                0.6551,
                1708059600
            ],
            [
                0.6684,
                1708405200
            ],
            [
                0.6592,
                1708491600
            ],
            [
                0.675,
                1708578000
            ],
            [
                0.6821,
                1708664400
            ],
            [
                0.7255,
                1708923600
            ],
            [
                0.7778,
                1709010000
            ],
            [
                0.7512,
                1709096400
            ],
            [
                0.67,
                1709182800
            ],
            [
                0.6601,
                1709269200
            ],
            [
                0.6821,
                1709528400
            ],
            [
                0.6722,
                1709614800
            ],
            [
                0.7,
                1709701200
            ],
            [
                0.7012,
                1709787600
            ],
            [
                0.6701,
                1709874000
            ],
            [
                0.67,
                1710129600
            ],
            [
                0.6692,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3303,
        "drug_name": "XIPERE (Suprachoroidal CLS-TA)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Macular edema associated with uveitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-25",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/bausch--lomb-and-clearside-biomedical-announce-fda-approval-of-xipere-triamcinolone-acetonide-injectable-suspension-for-suprachoroidal-use-for-the-treatment-of-macular-edema-associated-with-uveitis-301407260.html",
        "note": "Approved October 25, 2021. ",
        "company_entity_id": 574,
        "company_ticker": "BHC",
        "company_name": "Bausch Health Companies Inc.",
        "company_price": "9.1900",
        "company_change": 0.07,
        "company_percent_change": 0.77,
        "company_optionable": 1,
        "company_number_of_shares": 365411953,
        "price_change_sparkline": [
            [
                7.85,
                1706677200
            ],
            [
                7.98,
                1706763600
            ],
            [
                7.92,
                1706850000
            ],
            [
                7.77,
                1707109200
            ],
            [
                8.13,
                1707195600
            ],
            [
                8.12,
                1707282000
            ],
            [
                8.13,
                1707368400
            ],
            [
                8.21,
                1707454800
            ],
            [
                8.38,
                1707714000
            ],
            [
                8.41,
                1707800400
            ],
            [
                8.43,
                1707886800
            ],
            [
                8.49,
                1707973200
            ],
            [
                8.51,
                1708059600
            ],
            [
                8.6,
                1708405200
            ],
            [
                8.67,
                1708491600
            ],
            [
                9.3,
                1708578000
            ],
            [
                9.18,
                1708664400
            ],
            [
                8.99,
                1708923600
            ],
            [
                9.18,
                1709010000
            ],
            [
                9.2,
                1709096400
            ],
            [
                9.39,
                1709182800
            ],
            [
                9.89,
                1709269200
            ],
            [
                9.58,
                1709528400
            ],
            [
                9.56,
                1709614800
            ],
            [
                9.23,
                1709701200
            ],
            [
                9.28,
                1709787600
            ],
            [
                9.23,
                1709874000
            ],
            [
                9.12,
                1710129600
            ],
            [
                9.19,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3303,
        "drug_name": "XIPERE (Suprachoroidal CLS-TA)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Macular edema associated with uveitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-25",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/bausch--lomb-and-clearside-biomedical-announce-fda-approval-of-xipere-triamcinolone-acetonide-injectable-suspension-for-suprachoroidal-use-for-the-treatment-of-macular-edema-associated-with-uveitis-301407260.html",
        "note": "Approved October 25, 2021. ",
        "company_entity_id": 325,
        "company_ticker": "CLSD",
        "company_name": "Clearside Biomedical Inc.",
        "company_price": "1.6400",
        "company_change": -0.38,
        "company_percent_change": -18.81,
        "company_optionable": 1,
        "company_number_of_shares": 62408866,
        "price_change_sparkline": [
            [
                1.25,
                1706677200
            ],
            [
                1.33,
                1706763600
            ],
            [
                1.37,
                1706850000
            ],
            [
                1.39,
                1707109200
            ],
            [
                1.41,
                1707195600
            ],
            [
                1.38,
                1707282000
            ],
            [
                1.38,
                1707368400
            ],
            [
                1.42,
                1707454800
            ],
            [
                1.38,
                1707714000
            ],
            [
                1.3,
                1707800400
            ],
            [
                1.23,
                1707886800
            ],
            [
                1.22,
                1707973200
            ],
            [
                1.25,
                1708059600
            ],
            [
                1.29,
                1708405200
            ],
            [
                1.3,
                1708491600
            ],
            [
                1.33,
                1708578000
            ],
            [
                1.36,
                1708664400
            ],
            [
                1.34,
                1708923600
            ],
            [
                1.395,
                1709010000
            ],
            [
                1.41,
                1709096400
            ],
            [
                1.4,
                1709182800
            ],
            [
                1.39,
                1709269200
            ],
            [
                1.39,
                1709528400
            ],
            [
                1.39,
                1709614800
            ],
            [
                1.51,
                1709701200
            ],
            [
                1.67,
                1709787600
            ],
            [
                1.67,
                1709874000
            ],
            [
                2.02,
                1710129600
            ],
            [
                1.64,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7098,
        "drug_name": "VUITY",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Presbyopia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-10-29",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/us-food-and-drug-administration-approves-vuity-pilocarpine-hci-ophthalmic-solution-1-25-the-first-and-only-eye-drop-to-treat-presbyopia-age-related-blurry-near-vision-301412259.html",
        "note": "Approved October 29, 2021.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5078,
        "drug_name": "YUTREPIA (treprostinil)",
        "clinical_trial_id": "NCT04691154",
        "has_trial_insight_page": 0,
        "indication": "Pulmonary arterial hypertension",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-11-08",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/11\/08\/2328998\/0\/en\/FDA-Grants-Tentative-Approval-for-Liquidia-s-YUTREPIA-Treprostinil-Inhalation-Powder.html",
        "note": "Tentative approval November 8, 2021. Final approval due in October 2022 or earlier upon resolution of on-going litigation.",
        "company_entity_id": 583,
        "company_ticker": "LQDA",
        "company_name": "Liquidia Corporation",
        "company_price": "13.9800",
        "company_change": 0.37,
        "company_percent_change": 2.7199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 64905495,
        "price_change_sparkline": [
            [
                12.78,
                1706677200
            ],
            [
                13.6,
                1706763600
            ],
            [
                13.58,
                1706850000
            ],
            [
                13.54,
                1707109200
            ],
            [
                13.54,
                1707195600
            ],
            [
                14.58,
                1707282000
            ],
            [
                14.68,
                1707368400
            ],
            [
                14.81,
                1707454800
            ],
            [
                15.06,
                1707714000
            ],
            [
                14.31,
                1707800400
            ],
            [
                14.8,
                1707886800
            ],
            [
                14.83,
                1707973200
            ],
            [
                14.59,
                1708059600
            ],
            [
                14.13,
                1708405200
            ],
            [
                14.255,
                1708491600
            ],
            [
                14.04,
                1708578000
            ],
            [
                14.32,
                1708664400
            ],
            [
                14.62,
                1708923600
            ],
            [
                14.69,
                1709010000
            ],
            [
                14.385,
                1709096400
            ],
            [
                14.16,
                1709182800
            ],
            [
                14.52,
                1709269200
            ],
            [
                13.69,
                1709528400
            ],
            [
                13.79,
                1709614800
            ],
            [
                13.63,
                1709701200
            ],
            [
                13.66,
                1709787600
            ],
            [
                14.04,
                1709874000
            ],
            [
                13.61,
                1710129600
            ],
            [
                13.98,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6501,
        "drug_name": "EPRONTIA (topiramate) - Oral Solution",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Seizures\/migraine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-11-08",
        "link": "https:\/\/ir.etonpharma.com\/news-releases\/news-release-details\/eton-pharmaceuticals-and-azurity-pharmaceuticals-inc-announce",
        "note": "FDA Approval November 8, 2021.",
        "company_entity_id": 611,
        "company_ticker": "ETON",
        "company_name": "Eton Pharmaceuticals Inc.",
        "company_price": "4.4000",
        "company_change": -0.16000000000000003,
        "company_percent_change": -3.51,
        "company_optionable": 1,
        "company_number_of_shares": 25658396,
        "price_change_sparkline": [
            [
                4.67,
                1706677200
            ],
            [
                4.6,
                1706763600
            ],
            [
                4.49,
                1706850000
            ],
            [
                4.58,
                1707109200
            ],
            [
                4.72,
                1707195600
            ],
            [
                4.58,
                1707282000
            ],
            [
                4.41,
                1707368400
            ],
            [
                4.41,
                1707454800
            ],
            [
                4.41,
                1707714000
            ],
            [
                4.42,
                1707800400
            ],
            [
                4.39,
                1707886800
            ],
            [
                4.59,
                1707973200
            ],
            [
                4.4,
                1708059600
            ],
            [
                4.36,
                1708405200
            ],
            [
                4.45,
                1708491600
            ],
            [
                4.47,
                1708578000
            ],
            [
                4.47,
                1708664400
            ],
            [
                4.47,
                1708923600
            ],
            [
                4.49,
                1709010000
            ],
            [
                4.48,
                1709096400
            ],
            [
                4.45,
                1709182800
            ],
            [
                4.46,
                1709269200
            ],
            [
                4.47,
                1709528400
            ],
            [
                4.38,
                1709614800
            ],
            [
                4.33,
                1709701200
            ],
            [
                4.49,
                1709787600
            ],
            [
                4.5,
                1709874000
            ],
            [
                4.56,
                1710129600
            ],
            [
                4.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7750,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Renal cell carcinoma (RCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-11-18",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211118005576\/en\/",
        "note": "Approved November 18, 2021. ",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3410,
        "drug_name": "VOXZOGO (Vosoritide)",
        "clinical_trial_id": "NCT03197766",
        "has_trial_insight_page": 0,
        "indication": "Achondroplasia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-11-19",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/biomarin-receives-fda-approval-for-voxzogo-vosoritide-for-injection-indicated-to-increase-linear-growth-in-children-with-achondroplasia-aged-5-and-up-with-open-growth-plates-301429145.html",
        "note": "Approved November 19, 2021. ",
        "company_entity_id": 69,
        "company_ticker": "BMRN",
        "company_name": "BioMarin Pharmaceutical Inc.",
        "company_price": "85.1800",
        "company_change": -0.8200000000000001,
        "company_percent_change": -0.95,
        "company_optionable": 1,
        "company_number_of_shares": 188675622,
        "price_change_sparkline": [
            [
                88.08,
                1706677200
            ],
            [
                88.74,
                1706763600
            ],
            [
                88.11,
                1706850000
            ],
            [
                87.72,
                1707109200
            ],
            [
                89.8,
                1707195600
            ],
            [
                89.66,
                1707282000
            ],
            [
                88.15,
                1707368400
            ],
            [
                88.46,
                1707454800
            ],
            [
                88.18,
                1707714000
            ],
            [
                86.13,
                1707800400
            ],
            [
                86.01,
                1707886800
            ],
            [
                88.3,
                1707973200
            ],
            [
                88.77,
                1708059600
            ],
            [
                88.67,
                1708405200
            ],
            [
                88.54,
                1708491600
            ],
            [
                89.97,
                1708578000
            ],
            [
                91.24,
                1708664400
            ],
            [
                90.1,
                1708923600
            ],
            [
                90.68,
                1709010000
            ],
            [
                88.4,
                1709096400
            ],
            [
                86.28,
                1709182800
            ],
            [
                87.14,
                1709269200
            ],
            [
                87.72,
                1709528400
            ],
            [
                86.02,
                1709614800
            ],
            [
                86.77,
                1709701200
            ],
            [
                85.89,
                1709787600
            ],
            [
                85.95,
                1709874000
            ],
            [
                86,
                1710129600
            ],
            [
                85.18,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7880,
        "drug_name": "FYARRO",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "PEComa\u200b",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-11-23",
        "link": "https:\/\/ir.aadibio.com\/news-releases\/news-release-details\/aadi-bioscience-announces-fda-approval-its-first-product",
        "note": "Approved November 23, 2021.",
        "company_entity_id": 999,
        "company_ticker": "AADI",
        "company_name": "Aadi Bioscience Inc.",
        "company_price": "1.9400",
        "company_change": -0.20999999999999996,
        "company_percent_change": -9.77,
        "company_optionable": 1,
        "company_number_of_shares": 24525860,
        "price_change_sparkline": [
            [
                1.84,
                1706677200
            ],
            [
                1.76,
                1706763600
            ],
            [
                1.74,
                1706850000
            ],
            [
                1.7,
                1707109200
            ],
            [
                1.77,
                1707195600
            ],
            [
                1.75,
                1707282000
            ],
            [
                1.77,
                1707368400
            ],
            [
                1.87,
                1707454800
            ],
            [
                1.9,
                1707714000
            ],
            [
                1.78,
                1707800400
            ],
            [
                1.9,
                1707886800
            ],
            [
                1.9,
                1707973200
            ],
            [
                1.9,
                1708059600
            ],
            [
                1.91,
                1708405200
            ],
            [
                1.87,
                1708491600
            ],
            [
                1.89,
                1708578000
            ],
            [
                1.9,
                1708664400
            ],
            [
                1.98,
                1708923600
            ],
            [
                2.07,
                1709010000
            ],
            [
                2.07,
                1709096400
            ],
            [
                1.97,
                1709182800
            ],
            [
                1.92,
                1709269200
            ],
            [
                2.435,
                1709528400
            ],
            [
                2.11,
                1709614800
            ],
            [
                2.18,
                1709701200
            ],
            [
                2.22,
                1709787600
            ],
            [
                2.14,
                1709874000
            ],
            [
                2.15,
                1710129600
            ],
            [
                1.94,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7263,
        "drug_name": "TAK-620 (maribavir)",
        "clinical_trial_id": "NCT02931539",
        "has_trial_insight_page": 0,
        "indication": "Cytomegalovirus (CMV)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-11-23",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211123006185\/en\/",
        "note": "Approved November 23, 2021.",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5265,
        "drug_name": "PreHevbrio",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hepatitis B vaccine",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-01",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211201005387\/en\/",
        "note": "Approved December 1, 2021. ",
        "company_entity_id": 464,
        "company_ticker": "VBIV",
        "company_name": "VBI Vaccines Inc.",
        "company_price": "0.6190",
        "company_change": 0.02,
        "company_percent_change": 3.17,
        "company_optionable": 1,
        "company_number_of_shares": 23687695,
        "price_change_sparkline": [
            [
                0.7,
                1706677200
            ],
            [
                0.714,
                1706763600
            ],
            [
                0.689,
                1706850000
            ],
            [
                0.6649,
                1707109200
            ],
            [
                0.648,
                1707195600
            ],
            [
                0.639,
                1707282000
            ],
            [
                0.6505,
                1707368400
            ],
            [
                0.6799,
                1707454800
            ],
            [
                0.691,
                1707714000
            ],
            [
                0.66,
                1707800400
            ],
            [
                0.576,
                1707886800
            ],
            [
                0.6001,
                1707973200
            ],
            [
                0.6462,
                1708059600
            ],
            [
                0.6301,
                1708405200
            ],
            [
                0.631,
                1708491600
            ],
            [
                0.565,
                1708578000
            ],
            [
                0.5701,
                1708664400
            ],
            [
                0.5723,
                1708923600
            ],
            [
                0.565,
                1709010000
            ],
            [
                0.5603,
                1709096400
            ],
            [
                0.58,
                1709182800
            ],
            [
                0.59,
                1709269200
            ],
            [
                0.5759,
                1709528400
            ],
            [
                0.5812,
                1709614800
            ],
            [
                0.595,
                1709701200
            ],
            [
                0.5849,
                1709787600
            ],
            [
                0.58,
                1709874000
            ],
            [
                0.6,
                1710129600
            ],
            [
                0.619,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8654,
        "drug_name": "KYPROLIS (carfilzomib) with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and dexamethasone",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-01",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-new-kyprolis-carfilzomib-combination-regimen-with-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-and-dexamethasone-for-patients-with-multiple-myeloma-at-first-or-subsequent-relapse-301435467.html",
        "note": "Approved December 1, 2021.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8654,
        "drug_name": "KYPROLIS (carfilzomib) with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and dexamethasone",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Multiple Myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-01",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-new-kyprolis-carfilzomib-combination-regimen-with-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-and-dexamethasone-for-patients-with-multiple-myeloma-at-first-or-subsequent-relapse-301435467.html",
        "note": "Approved December 1, 2021.",
        "company_entity_id": 156,
        "company_ticker": "HALO",
        "company_name": "Halozyme Therapeutics Inc.",
        "company_price": "41.9500",
        "company_change": 0.75,
        "company_percent_change": 1.8199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 126824800,
        "price_change_sparkline": [
            [
                33.85,
                1706677200
            ],
            [
                34.26,
                1706763600
            ],
            [
                33.68,
                1706850000
            ],
            [
                33.68,
                1707109200
            ],
            [
                35.02,
                1707195600
            ],
            [
                35.31,
                1707282000
            ],
            [
                35.24,
                1707368400
            ],
            [
                35.49,
                1707454800
            ],
            [
                35.69,
                1707714000
            ],
            [
                34.64,
                1707800400
            ],
            [
                35.06,
                1707886800
            ],
            [
                35.91,
                1707973200
            ],
            [
                36.1,
                1708059600
            ],
            [
                36,
                1708405200
            ],
            [
                38.36,
                1708491600
            ],
            [
                39.72,
                1708578000
            ],
            [
                40.56,
                1708664400
            ],
            [
                39.67,
                1708923600
            ],
            [
                39.84,
                1709010000
            ],
            [
                39.69,
                1709096400
            ],
            [
                39.81,
                1709182800
            ],
            [
                41.11,
                1709269200
            ],
            [
                40.93,
                1709528400
            ],
            [
                41.41,
                1709614800
            ],
            [
                41.69,
                1709701200
            ],
            [
                41.71,
                1709787600
            ],
            [
                41.73,
                1709874000
            ],
            [
                41.2,
                1710129600
            ],
            [
                41.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8254,
        "drug_name": "Bamlanivimab and Etesevimab",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "COVID-19 Anti-body",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-03",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lillys-bamlanivimab-with-etesevimab-authorized-as-the-first-and-only-neutralizing-antibody-therapy-for-emergency-use-in-covid-19-patients-under-the-age-of-12-301437329.html",
        "note": "Emergency Use Authorization (EUA) expanded for children under 12 years old, noted December 3, 2021. ",
        "company_entity_id": 863,
        "company_ticker": "ABCL",
        "company_name": "AbCellera Biologics Inc.",
        "company_price": "4.8800",
        "company_change": -0.07999999999999996,
        "company_percent_change": -1.6099999999999999,
        "company_optionable": 1,
        "company_number_of_shares": 289355867,
        "price_change_sparkline": [
            [
                5.11,
                1706677200
            ],
            [
                5.2,
                1706763600
            ],
            [
                5.01,
                1706850000
            ],
            [
                4.95,
                1707109200
            ],
            [
                5.18,
                1707195600
            ],
            [
                4.91,
                1707282000
            ],
            [
                5.02,
                1707368400
            ],
            [
                5.11,
                1707454800
            ],
            [
                5.46,
                1707714000
            ],
            [
                5.11,
                1707800400
            ],
            [
                5.22,
                1707886800
            ],
            [
                5.28,
                1707973200
            ],
            [
                5.34,
                1708059600
            ],
            [
                5.31,
                1708405200
            ],
            [
                4.81,
                1708491600
            ],
            [
                4.85,
                1708578000
            ],
            [
                4.87,
                1708664400
            ],
            [
                4.95,
                1708923600
            ],
            [
                5.12,
                1709010000
            ],
            [
                5.08,
                1709096400
            ],
            [
                5.05,
                1709182800
            ],
            [
                5.05,
                1709269200
            ],
            [
                5,
                1709528400
            ],
            [
                4.81,
                1709614800
            ],
            [
                4.87,
                1709701200
            ],
            [
                4.91,
                1709787600
            ],
            [
                4.77,
                1709874000
            ],
            [
                4.96,
                1710129600
            ],
            [
                4.88,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8254,
        "drug_name": "Bamlanivimab and Etesevimab",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "COVID-19 Anti-body",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-03",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lillys-bamlanivimab-with-etesevimab-authorized-as-the-first-and-only-neutralizing-antibody-therapy-for-emergency-use-in-covid-19-patients-under-the-age-of-12-301437329.html",
        "note": "Emergency Use Authorization (EUA) expanded for children under 12 years old, noted December 3, 2021. ",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8081,
        "drug_name": "KEYTRUDA (pembrolizumab) - (KEYNOTE-716)",
        "clinical_trial_id": "NCT03553836",
        "has_trial_insight_page": 0,
        "indication": "IIB or IIC Melanoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-03",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211203005607\/en\/",
        "note": "Approved December 3, 2021. ",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5328,
        "drug_name": "DARE-BV1",
        "clinical_trial_id": "NCT04370548",
        "has_trial_insight_page": 0,
        "indication": "Bacterial Vaginosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-07",
        "link": "https:\/\/ir.darebioscience.com\/news-releases\/news-release-details\/dare-announces-fda-approval-xaciatotm-clindamycin-phosphate",
        "note": "FDA Approval on December 7, 2021.",
        "company_entity_id": 432,
        "company_ticker": "DARE",
        "company_name": "Dare Bioscience Inc.",
        "company_price": "0.4601",
        "company_change": -0.040000000000000036,
        "company_percent_change": -8.04,
        "company_optionable": 0,
        "company_number_of_shares": 98562344,
        "price_change_sparkline": [
            [
                0.325,
                1706677200
            ],
            [
                0.344,
                1706763600
            ],
            [
                0.34,
                1706850000
            ],
            [
                0.3301,
                1707109200
            ],
            [
                0.336,
                1707195600
            ],
            [
                0.3326,
                1707282000
            ],
            [
                0.3451,
                1707368400
            ],
            [
                0.348,
                1707454800
            ],
            [
                0.362,
                1707714000
            ],
            [
                0.3502,
                1707800400
            ],
            [
                0.3611,
                1707886800
            ],
            [
                0.3657,
                1707973200
            ],
            [
                0.3613,
                1708059600
            ],
            [
                0.3426,
                1708405200
            ],
            [
                0.3618,
                1708491600
            ],
            [
                0.44,
                1708578000
            ],
            [
                0.5352,
                1708664400
            ],
            [
                0.4301,
                1708923600
            ],
            [
                0.5005,
                1709010000
            ],
            [
                0.5038,
                1709096400
            ],
            [
                0.574,
                1709182800
            ],
            [
                0.5499,
                1709269200
            ],
            [
                0.5501,
                1709528400
            ],
            [
                0.563,
                1709614800
            ],
            [
                0.5223,
                1709701200
            ],
            [
                0.493,
                1709787600
            ],
            [
                0.4951,
                1709874000
            ],
            [
                0.5,
                1710129600
            ],
            [
                0.4601,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5295,
        "drug_name": "ENTADFI (tadalafil and finasteride combo)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Benign prostatic hyperplasia (BPH)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-13",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/12\/13\/2350788\/11676\/en\/Veru-Announces-FDA-Approval-of-ENTADFI-a-New-Treatment-for-Benign-Prostatic-Hyperplasia.html",
        "note": "Approved December 13, 2021. ",
        "company_entity_id": 596,
        "company_ticker": "VERU",
        "company_name": "Veru Inc.",
        "company_price": "0.6310",
        "company_change": -0.030000000000000027,
        "company_percent_change": -4.1,
        "company_optionable": 1,
        "company_number_of_shares": 146381186,
        "price_change_sparkline": [
            [
                0.4877,
                1706677200
            ],
            [
                0.49,
                1706763600
            ],
            [
                0.5,
                1706850000
            ],
            [
                0.49,
                1707109200
            ],
            [
                0.4407,
                1707195600
            ],
            [
                0.44,
                1707282000
            ],
            [
                0.4111,
                1707368400
            ],
            [
                0.3798,
                1707454800
            ],
            [
                0.3875,
                1707714000
            ],
            [
                0.378,
                1707800400
            ],
            [
                0.4173,
                1707886800
            ],
            [
                0.42,
                1707973200
            ],
            [
                0.4838,
                1708059600
            ],
            [
                0.5041,
                1708405200
            ],
            [
                0.498,
                1708491600
            ],
            [
                0.555,
                1708578000
            ],
            [
                0.59,
                1708664400
            ],
            [
                0.5502,
                1708923600
            ],
            [
                0.6462,
                1709010000
            ],
            [
                0.6165,
                1709096400
            ],
            [
                0.6051,
                1709182800
            ],
            [
                0.64,
                1709269200
            ],
            [
                0.635,
                1709528400
            ],
            [
                0.5934,
                1709614800
            ],
            [
                0.642,
                1709701200
            ],
            [
                0.612,
                1709787600
            ],
            [
                0.6475,
                1709874000
            ],
            [
                0.66,
                1710129600
            ],
            [
                0.631,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6345,
        "drug_name": "XELJANZ (tofacitinib)",
        "clinical_trial_id": "NCT03502616",
        "has_trial_insight_page": 0,
        "indication": "Ankylosing spondylitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-14",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211214006245\/en\/",
        "note": "Approved December 14, 2021. ",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6386,
        "drug_name": "RINVOQ (Upadacitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Psoriatic arthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-15",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/rinvoq-upadacitinib-receives-us-fda-approval-for-active-psoriatic-arthritis-301444790.html",
        "note": "Approved December 15, 2021. ",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    }
]